Xu Wang1,2, Yoel Genaro Montoyo-Pujol1, Sandra Bermudez1, Gonzalo Corpas1, Aurelio Martin3, Francisco Almazan4, Teresa Cabrera5, Miguel Angel López-Nevot1,5,6. 1. Servicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de Las Nieves, Avda. Fuerzas Armadas s/n, Granada 18014, Spain. 2. Programa de Doctorado en Biomedicina, Universidad de Granada, Granada, Spain. 3. Servicio de Anatomía Patológica, Hospital Universitario Virgen de Las Nieves, Avda. Fuerzas Armadas s/n, Granada 18014, Spain. 4. Servicio de Dermatología, Hospital Universitario Clinico San Cecilio (PTS), Avenida de la Investigación s/n, Granada 18014, Spain. 5. Departamento Bioquímica, Biología Molecular e Inmunología III, Universidad de Granada, Granada, Spain. 6. Instituto de Investigación Biosanitaria I Ibs. GRANADA, Avda de Madrid 15, Pabellón de Consultas Externas 2, Granada 18012, Spain.
Abstract
PURPOSE: Previous studies have shown that melanoma cells produce excessive levels of cytokines, which have various biological roles during melanoma development. The aim of this study was to expand the profile of serum cytokines, chemokines, growth factors, and angiogenic factors that are associated with melanoma, to find more cytokines with abnormal concentrations in melanoma patients, to identify whether the level of cytokines correlated with prognostic variants, such as Breslow thickness and BRAF mutation, and, finally, to find out the cytokines that play important roles during melanoma development. MATERIALS AND METHODS: Multiplex immunobead assay technology and 45-plex immunoassays ProcartaPlex™ kits were used to simultaneously compare the levels of cytokines, growth factors, angiogenic factors, and chemokines between the serum of healthy patients (n = 30) and those with melanoma (n = 72). Data were analyzed according to the clinical characteristics of the designated patient subgroups. RESULTS: Compared to the control group, melanoma patients had higher levels of VEGF-A, PDGF-BB, IL-1RA, PIGF-1, IFN-γ, TNF-α, MIP-1α, and SCF, but lower levels of BDNF, SDF-1α, MCP-1, Eotaxin, EGF, and IL-7. Furthermore, the levels of TNF-α (P=0.320, r = 0.019), IFN-γ (P=0.311, r = 0.023), VEGF-A (P=0.014, r = 0.337), and BDNF (0.004, r = -0.391) showed a significant correlation with Breslow thickness. IL-7 was of lower levels in patients harboring BRAF mutants. Melanoma patients with high levels of MIP-1α and MCP-1 showed the poorest overall survival. CONCLUSIONS: We found that the levels of VEGF-A and PDGF-BB in the serum of both primary and metastatic melanoma patients are elevated. TNF-α, IFN-γ, and VEGF-A presented a positive correlation with Breslow thickness, whereas BDNF showed a negative association. MIP-1α and MCP-1 correlated negatively with survival. In addition, lower levels of IL-7 were found in patients harboring BRAF mutants. These findings indicate that these cytokines may play critical roles in the progression of melanoma.
PURPOSE: Previous studies have shown that melanoma cells produce excessive levels of cytokines, which have various biological roles during melanoma development. The aim of this study was to expand the profile of serum cytokines, chemokines, growth factors, and angiogenic factors that are associated with melanoma, to find more cytokines with abnormal concentrations in melanoma patients, to identify whether the level of cytokines correlated with prognostic variants, such as Breslow thickness and BRAF mutation, and, finally, to find out the cytokines that play important roles during melanoma development. MATERIALS AND METHODS: Multiplex immunobead assay technology and 45-plex immunoassays ProcartaPlex™ kits were used to simultaneously compare the levels of cytokines, growth factors, angiogenic factors, and chemokines between the serum of healthy patients (n = 30) and those with melanoma (n = 72). Data were analyzed according to the clinical characteristics of the designated patient subgroups. RESULTS: Compared to the control group, melanoma patients had higher levels of VEGF-A, PDGF-BB, IL-1RA, PIGF-1, IFN-γ, TNF-α, MIP-1α, and SCF, but lower levels of BDNF, SDF-1α, MCP-1, Eotaxin, EGF, and IL-7. Furthermore, the levels of TNF-α (P=0.320, r = 0.019), IFN-γ (P=0.311, r = 0.023), VEGF-A (P=0.014, r = 0.337), and BDNF (0.004, r = -0.391) showed a significant correlation with Breslow thickness. IL-7 was of lower levels in patients harboring BRAF mutants. Melanoma patients with high levels of MIP-1α and MCP-1 showed the poorest overall survival. CONCLUSIONS: We found that the levels of VEGF-A and PDGF-BB in the serum of both primary and metastatic melanoma patients are elevated. TNF-α, IFN-γ, and VEGF-A presented a positive correlation with Breslow thickness, whereas BDNF showed a negative association. MIP-1α and MCP-1 correlated negatively with survival. In addition, lower levels of IL-7 were found in patients harboring BRAF mutants. These findings indicate that these cytokines may play critical roles in the progression of melanoma.
Authors: Dirk Schadendorf; Alexander C J van Akkooi; Carola Berking; Klaus G Griewank; Ralf Gutzmer; Axel Hauschild; Andreas Stang; Alexander Roesch; Selma Ugurel Journal: Lancet Date: 2018-09-15 Impact factor: 79.321
Authors: Nisha Nagarkatti-Gude; Inge H G Bronkhorst; Sjoerd G van Duinen; Gregorius P M Luyten; Martine J Jager Journal: Invest Ophthalmol Vis Sci Date: 2012-10-01 Impact factor: 4.799
Authors: Liang Cheng; Antonio Lopez-Beltran; Francesco Massari; Gregory T MacLennan; Rodolfo Montironi Journal: Mod Pathol Date: 2017-11-17 Impact factor: 7.842